β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)

The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects. Previous studies have reported that chronic microinflammation, which occurs in diseases, includ...

Full description

Saved in:
Bibliographic Details
Published inOncology reports Vol. 47; no. 1
Main Authors Ikewaki, Nobunao, Dedeepiya, Vidyasagar, Raghavan, Kadalraja, Rao, Kosagi-Sharaf, Vaddi, Suryaprakash, Osawa, Hiroshi, Kisaka, Tomohiko, Kurosawa, Gene, Srinivasan, Subramaniam, Kumar, Seydunganallu, Senthilkumar, Rajappa, Iwasaki, Masaru, Preethy, Senthilkumar, Abraham, Samuel
Format Journal Article
LanguageEnglish
Published Greece Spandidos Publications UK Ltd 01.01.2022
Subjects
Adjuvants, Vaccine - administration & dosage
Aging
Animals
Antigens
beta-Glucans - immunology
Cancer therapies
Chemotherapy
Cytotoxicity
Diabetes
Disease prevention
DNA damage
Health risk assessment
Humans
Hyperglycemia
Hypothalamus
Immune system
Immunocompromised Host - immunology
Inflammation
Metabolic disorders
Mortality
Neoplasms - immunology
Neoplasms - prevention & control
Older people
Phytochemicals
Prostate cancer
Radiation therapy
Surgery
Vaccines
vaccine adjuvant
cancer
β‑glucan
immune weakness
Online AccessGet full text

Cover

Abstract The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects. Previous studies have reported that chronic microinflammation, which occurs in diseases, including diabetes, along with weakened immune systems, may ultimately lead to cancer development. Chemotherapy, radiotherapy and surgery are the mainstream approaches to treatment; however, they all lead to immune system weakness, which in turn increases the metastatic spread. The aim of the present review was to provide evidence of a biological response modifier β‑glucan [β‑glucan vaccine adjuvant approach to treating cancer via immune enhancement (B‑VACCIEN)] and its beneficial effects, including vaccine‑adjuvant potential, balancing metabolic parameters (including blood glucose and lipid levels), increasing peripheral blood cell cytotoxicity against cancer and alleviating chemotherapy side effects in animal models. This suggests its value as a potential strategy to provide long‑term prophylaxis in immunocompromised individuals or genetically prone to cancer.
AbstractList The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects. Previous studies have reported that chronic microinflammation, which occurs in diseases, including diabetes, along with weakened immune systems, may ultimately lead to cancer development. Chemotherapy, radiotherapy and surgery are the mainstream approaches to treatment; however, they all lead to immune system weakness, which in turn increases the metastatic spread. The aim of the present review was to provide evidence of a biological response modifier β‑glucan [β‑glucan vaccine adjuvant approach to treating cancer via immune enhancement (B‑VACCIEN)] and its beneficial effects, including vaccine‑adjuvant potential, balancing metabolic parameters (including blood glucose and lipid levels), increasing peripheral blood cell cytotoxicity against cancer and alleviating chemotherapy side effects in animal models. This suggests its value as a potential strategy to provide long‑term prophylaxis in immunocompromised individuals or genetically prone to cancer.
The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects. Previous studies have reported that chronic microinflammation, which occurs in diseases, including diabetes, along with weakened immune systems, may ultimately lead to cancer development. Chemotherapy, radiotherapy and surgery are the mainstream approaches to treatment; however, they all lead to immune system weakness, which in turn increases the metastatic spread. The aim of the present review was to provide evidence of a biological response modifier β‑glucan [β‑glucan vaccine adjuvant approach to treating cancer via immune enhancement (B‑VACCIEN)] and its beneficial effects, including vaccine‑adjuvant potential, balancing metabolic parameters (including blood glucose and lipid levels), increasing peripheral blood cell cytotoxicity against cancer and alleviating chemotherapy side effects in animal models. This suggests its value as a potential strategy to provide long‑term prophylaxis in immunocompromised individuals or genetically prone to cancer.The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify effective treatments with fewer side‑effects. Previous studies have reported that chronic microinflammation, which occurs in diseases, including diabetes, along with weakened immune systems, may ultimately lead to cancer development. Chemotherapy, radiotherapy and surgery are the mainstream approaches to treatment; however, they all lead to immune system weakness, which in turn increases the metastatic spread. The aim of the present review was to provide evidence of a biological response modifier β‑glucan [β‑glucan vaccine adjuvant approach to treating cancer via immune enhancement (B‑VACCIEN)] and its beneficial effects, including vaccine‑adjuvant potential, balancing metabolic parameters (including blood glucose and lipid levels), increasing peripheral blood cell cytotoxicity against cancer and alleviating chemotherapy side effects in animal models. This suggests its value as a potential strategy to provide long‑term prophylaxis in immunocompromised individuals or genetically prone to cancer.
ArticleNumber 14
Author Kisaka, Tomohiko
Kumar, Seydunganallu
Kurosawa, Gene
Senthilkumar, Rajappa
Srinivasan, Subramaniam
Osawa, Hiroshi
Iwasaki, Masaru
Rao, Kosagi-Sharaf
Dedeepiya, Vidyasagar
Abraham, Samuel
Ikewaki, Nobunao
Vaddi, Suryaprakash
Raghavan, Kadalraja
Preethy, Senthilkumar
Author_xml – sequence: 1
  givenname: Nobunao
  surname: Ikewaki
  fullname: Ikewaki, Nobunao
  organization: Department of Medical Life Science, Kyushu University of Health and Welfare, Nobeoka, Miyazaki 882‑8508, Japan
– sequence: 2
  givenname: Vidyasagar
  surname: Dedeepiya
  fullname: Dedeepiya, Vidyasagar
  organization: The Mary‑Yoshio Translational Hexagon (MYTH), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai 600034, India
– sequence: 3
  givenname: Kadalraja
  surname: Raghavan
  fullname: Raghavan, Kadalraja
  organization: Department of Paediatric Neurology, Kenmax Medical Service Private Limited, Tallakulam, Madurai 625002, India
– sequence: 4
  givenname: Kosagi-Sharaf
  surname: Rao
  fullname: Rao, Kosagi-Sharaf
  organization: Institute of Scientific Research and High Technology Services of Panama (INDICASAT‑AIP), Clayton 88888, Republic of Panama
– sequence: 5
  givenname: Suryaprakash
  surname: Vaddi
  fullname: Vaddi, Suryaprakash
  organization: Department of Urology, Yashoda Hospitals, Hyderabad, Telangana 50008, India
– sequence: 6
  givenname: Hiroshi
  surname: Osawa
  fullname: Osawa, Hiroshi
  organization: Clinical Services Department, Omote Medical Clinic, Chiba 296‑8602, Japan
– sequence: 7
  givenname: Tomohiko
  surname: Kisaka
  fullname: Kisaka, Tomohiko
  organization: Division of Biodesign, Office of Research and Academic‑Government‑Community Collaboration, Hiroshima University, Higashihiroshima, Hiroshima 739‑8511, Japan
– sequence: 8
  givenname: Gene
  surname: Kurosawa
  fullname: Kurosawa, Gene
  organization: Department of Academic Research Support Promotion Facility, Center for Research Promotion and Support, Fujita Health University, Toyoake, Aichi 470‑1192, Japan
– sequence: 9
  givenname: Subramaniam
  surname: Srinivasan
  fullname: Srinivasan, Subramaniam
  organization: The Mary‑Yoshio Translational Hexagon (MYTH), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai 600034, India
– sequence: 10
  givenname: Seydunganallu
  surname: Kumar
  fullname: Kumar, Seydunganallu
  organization: Department of Sociology, Manonmaniyam Sundaranar University, Abishekapatti, Tamil Nadu 627012, India
– sequence: 11
  givenname: Rajappa
  surname: Senthilkumar
  fullname: Senthilkumar, Rajappa
  organization: The Fujio‑Eiji Academic Terrain (FEAT), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai 600034, India
– sequence: 12
  givenname: Masaru
  surname: Iwasaki
  fullname: Iwasaki, Masaru
  organization: Centre for Advancing Clinical Research (CACR), University of Yamanashi‑ School of Medicine, Chuo, Yamanashi 409‑3898, Japan
– sequence: 13
  givenname: Senthilkumar
  surname: Preethy
  fullname: Preethy, Senthilkumar
  organization: The Fujio‑Eiji Academic Terrain (FEAT), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai 600034, India
– sequence: 14
  givenname: Samuel
  surname: Abraham
  fullname: Abraham, Samuel
  organization: The Mary‑Yoshio Translational Hexagon (MYTH), Nichi‑In Centre for Regenerative Medicine (NCRM), Chennai 600034, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34779494$$D View this record in MEDLINE/PubMed
BookMark eNpt0c1u1DAQAGALFdEfuHFGlrhspWbxT7xOju2qQKUKJASIWzRxJl2vEju1k0Xc-gq98CA8SB-CJ8HbLRwqTh55vhmNZg7JnvMOCXnJ2VwWpXjjw1wwweeFEOoJOeC65JnIJd9LcfrPpFTf9slhjGvGhGaL8hnZl7nWZV7mB-Tn3a_fN7dX3WTA0Q0YYx1SaNbTBtxIYRiCB7OirQ80CYOBjgFh7DFlx1Xw09WK2r6fUhW61Vbcp2ZnqevX0-Xy4vzDMbWOxgGNba3ZYW98nzr3NmJDBz9MHYzWu0hnn3Bj8fvxc_K0hS7ii4f3iHx5e_55-T67_PjuYnl6mRmp9JhJoTkukANbSMDGiLqsIecMZIFGcFBSFnVdl2WrUUkNOSBXumHC5Kxp61wekdmub5rmesI4Vmkmg10HDv0UK6FKXfBCMp3o60d07afg0nSVWDCluORMJfXqQU11j001BNtD-FH93XgCJztggo8xYPuPcFZtD1r5UG0PWm0Pmrh4xI0d75c1BrDd_4v-AE2_p-4
CitedBy_id crossref_primary_10_1016_j_ijbiomac_2023_126998
crossref_primary_10_1016_j_ijbiomac_2024_132986
crossref_primary_10_3389_fpubh_2024_1495056
crossref_primary_10_3390_vaccines13010064
crossref_primary_10_37489_0235_2990_2023_68_3_4_25_29
crossref_primary_10_3389_fnut_2023_1143682
crossref_primary_10_30895_2221_996X_2022_22_3_308_317
crossref_primary_10_3389_fimmu_2025_1538147
crossref_primary_10_3389_fimmu_2022_852147
crossref_primary_10_1016_j_ijbiomac_2023_123617
crossref_primary_10_4062_biomolther_2024_047
crossref_primary_10_17776_csj_1336167
crossref_primary_10_1540_jsmr_59_67
Cites_doi 10.1155/2012/895370
10.1016/S0140-6736(00)03231-1
10.1111/j.1365-2567.2007.02587.x
10.1158/1940-6207.CAPR-16-0209
10.1186/s12979-016-0068-x
10.1007/s12070-013-0623-0
10.1186/s12979-017-0112-5
10.1007/s11033-020-05459-7
10.3389/fchem.2020.00601
10.4240/wjgs.v4.i3.62
10.1111/j.1348-0421.2007.tb03982.x
10.1158/2326-6066.CIR-14-0110
10.1016/j.vaccine.2018.07.038
10.14336/AD.2016.0118
10.1016/j.cell.2020.09.058
10.1186/s13048-020-00626-7
10.32388/F1TWFR
10.1038/nature09638
10.1172/JCI80009
10.1155/2017/8972678
10.1055/s-2008-1062739
10.1161/01.CIR.0000034509.14906.AE
10.1016/j.cmet.2019.05.021
10.3390/nu13010242
10.1016/j.foodchem.2020.127982
10.4014/jmb.1011.11024
10.1016/j.clicom.2021.11.001
10.3389/fimmu.2020.01782
10.1080/21645515.2021.1880210
10.3390/ijms18081787
10.1038/s41577-020-00447-1
10.1016/S1470-2045(03)01282-8
10.21037/atm.2016.04.01
10.1016/j.clnu.2020.11.029
10.3390/molecules24071251
10.1097/NNR.0b013e31818fcecd
10.1016/j.biopha.2021.112243
10.3109/19390211.2013.859211
10.7554/eLife.04177
10.1007/978-1-4939-7104-6_11
10.3389/fimmu.2020.564497
10.1155/2012/195956
10.2183/pjab.94.011
10.1007/978-1-4939-3387-7_43
10.3347/kjp.2009.47.4.345
10.1089/jir.2018.0087
10.1186/s12943-017-0721-9
10.3390/ijms20204981
10.3389/fimmu.2018.00341
10.3390/ijms20153618
10.3390/ijms20164032
10.3889/oamjms.2019.589
ContentType Journal Article
Copyright Copyright Spandidos Publications UK Ltd. 2022
Copyright_xml – notice: Copyright Spandidos Publications UK Ltd. 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.3892/or.2021.8225
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central
ProQuest One
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
British Nursing Index with Full Text
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest One Academic Middle East (New)
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1791-2431
ExternalDocumentID 34779494
10_3892_or_2021_8225
Genre Journal Article
Review
GroupedDBID ---
0R~
2WC
53G
7X7
88E
8FI
8FJ
AAYXX
ABJNI
ABUWG
ACGFS
ADBBV
AEGXH
AENEX
AFKRA
AFOSN
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AN0
BAWUL
BENPR
BNQBC
BPHCQ
BVXVI
C45
CCPQU
CITATION
CS3
DIK
E3Z
EBD
EBS
EJD
EMOBN
F5P
FYUFA
GX1
H13
HMCUK
HUR
HZ~
IAO
IHR
IHW
INH
INR
IPNFZ
ITC
M1P
O9-
OK1
OVD
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
RIG
SV3
TEORI
TR2
UKHRP
123
3V.
ABPMR
CGR
CUY
CVF
ECM
EIF
FRP
NPM
ODZKP
OGEVE
UDS
W2D
7XB
8FK
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c357t-3271e6e1a063aedc2b9ba410a38ec21a5338bbb99f7e537a4ae157d02c40dfb43
IEDL.DBID 7X7
ISSN 1021-335X
1791-2431
IngestDate Fri Jul 11 08:14:47 EDT 2025
Fri Jul 25 06:36:52 EDT 2025
Thu Jan 02 22:57:04 EST 2025
Thu Apr 24 23:01:09 EDT 2025
Tue Jul 01 02:36:01 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 1
Keywords vaccine adjuvant
cancer
β‑glucan
immune weakness
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c357t-3271e6e1a063aedc2b9ba410a38ec21a5338bbb99f7e537a4ae157d02c40dfb43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.spandidos-publications.com/10.3892/or.2021.8225/download
PMID 34779494
PQID 2605513105
PQPubID 2044953
ParticipantIDs proquest_miscellaneous_2597818307
proquest_journals_2605513105
pubmed_primary_34779494
crossref_primary_10_3892_or_2021_8225
crossref_citationtrail_10_3892_or_2021_8225
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-01-01
PublicationDateYYYYMMDD 2022-01-01
PublicationDate_xml – month: 01
  year: 2022
  text: 2022-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Greece
PublicationPlace_xml – name: Greece
– name: Athens
PublicationTitle Oncology reports
PublicationTitleAlternate Oncol Rep
PublicationYear 2022
Publisher Spandidos Publications UK Ltd
Publisher_xml – name: Spandidos Publications UK Ltd
References Crunkhorn (key20220302131530_b20-or-47-01-08225) 2020; 20
Imai (key20220302131530_b6-or-47-01-08225) 2000; 356
De Maria (key20220302131530_b22-or-47-01-08225)
Zaidi (key20220302131530_b52-or-47-01-08225) 2019; 39
Kalafati (key20220302131530_b29-or-47-01-08225) 2020; 183
Kang (key20220302131530_b11-or-47-01-08225) 2009; 58
Melief (key20220302131530_b16-or-47-01-08225) 2015; 125
Seya (key20220302131530_b28-or-47-01-08225) 2018; 94
Ma (key20220302131530_b64-or-47-01-08225) 2016; 7
Du (key20220302131530_b27-or-47-01-08225) 2019; 18
Lazarus (key20220302131530_b23-or-47-01-08225) 2011; 27
Liefvendahl (key20220302131530_b8-or-47-01-08225) 2008; 40
Yano (key20220302131530_b62-or-47-01-08225)
National Cancer Institute (key20220302131530_b68-or-47-01-08225)
Chiba (key20220302131530_b54-or-47-01-08225) 2014; 3
Coffey (key20220302131530_b12-or-47-01-08225) 2003; 4
Finn (key20220302131530_b15-or-47-01-08225) 2014; 2
Pifferi (key20220302131530_b21-or-47-01-08225) 2021; 25
Bayindir (key20220302131530_b67-or-47-01-08225) 2014; 66
Mirza (key20220302131530_b33-or-47-01-08225) 2017; 1625
Cognigni (key20220302131530_b31-or-47-01-08225) 2021; 2
Zhao (key20220302131530_b53-or-47-01-08225) 2018; 15
Jin (key20220302131530_b32-or-47-01-08225) 2018; 36
Steimbach (key20220302131530_b65-or-47-01-08225) 2021; 40
National Cancer (key20220302131530_b5-or-47-01-08225)
Barera (key20220302131530_b46-or-47-01-08225) 2016; 7
Wu (key20220302131530_b7-or-47-01-08225) 2016; 3
Chaichian (key20220302131530_b30-or-47-01-08225) 2020; 13
Kim (key20220302131530_b2-or-47-01-08225) 2007; 121
British Society of Immunology (key20220302131530_b18-or-47-01-08225)
Ikewaki (key20220302131530_b38-or-47-01-08225) 2021; 3
Kozlowski (key20220302131530_b49-or-47-01-08225) 2007; 45
Esposito (key20220302131530_b9-or-47-01-08225) 2002; 106
Vetvicka (key20220302131530_b26-or-47-01-08225) 2019; 24
Eiró (key20220302131530_b41-or-47-01-08225) 2012; 4
Sadeghi (key20220302131530_b40-or-47-01-08225) 2020; 47
Papaioannou (key20220302131530_b66-or-47-01-08225) 2016; 4
Paris (key20220302131530_b34-or-47-01-08225) 2020; 8
Setrerrahmane (key20220302131530_b50-or-47-01-08225) 2017; 16
Ikewaki (key20220302131530_b60-or-47-01-08225)
Raguindin (key20220302131530_b25-or-47-01-08225) 2021; 5
Leonardi (key20220302131530_b3-or-47-01-08225) 2018; 15
Ikewaki (key20220302131530_b59-or-47-01-08225)
Vetvicka (key20220302131530_b39-or-47-01-08225) 2018; 38
Geller (key20220302131530_b69-or-47-01-08225) 2019; 20
Camous (key20220302131530_b4-or-47-01-08225) 2012; 2012
Hu (key20220302131530_b19-or-47-01-08225) 2020; 8
Raghavan (key20220302131530_b58-or-47-01-08225) 2021
Bacha (key20220302131530_b45-or-47-01-08225) 2017; 2017
Dedeepiya (key20220302131530_b43-or-47-01-08225) 2012; 2012
Cai (key20220302131530_b10-or-47-01-08225) 2019; 30
Centers for Disease Control and Prevention (key20220302131530_b14-or-47-01-08225)
Hong (key20220302131530_b36-or-47-01-08225) 2003; 15
World Health Organization (WHO) (key20220302131530_b1-or-47-01-08225)
Angka (key20220302131530_b13-or-47-01-08225) 2017; 18
Yatawara (key20220302131530_b55-or-47-01-08225) 2009; 47
Suzuki (key20220302131530_b63-or-47-01-08225) 2021; 13
Ganesh (key20220302131530_b44-or-47-01-08225) 2014; 11
Kimura (key20220302131530_b61-or-47-01-08225) 2006; 26
Ranjan (key20220302131530_b24-or-47-01-08225) 2019; 20
Qazi (key20220302131530_b48-or-47-01-08225) 2011; 2011
Ikewaki (key20220302131530_b57-or-47-01-08225)
Ikewaki (key20220302131530_b47-or-47-01-08225) 2007; 51
Chonov (key20220302131530_b51-or-47-01-08225) 2019; 7
Thomas (key20220302131530_b17-or-47-01-08225) 2016; 1403
Le (key20220302131530_b56-or-47-01-08225) 2011; 21
Zhang (key20220302131530_b35-or-47-01-08225) 2018; 26
Geller (key20220302131530_b37-or-47-01-08225) 2020; 11
Todoric (key20220302131530_b42-or-47-01-08225) 2016; 9
References_xml – ident: key20220302131530_b22-or-47-01-08225
  article-title: Carbohydrate oxidases. Patent Ref. No: WO2011009747A1
– ident: key20220302131530_b18-or-47-01-08225
  article-title: Adjuvants: Introduction. British Society of immunology
– volume: 2012
  start-page: 895370
  year: 2012
  ident: key20220302131530_b43-or-47-01-08225
  article-title: Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: Preliminary findings from the study on three patients from India
  publication-title: Case Rep Med
  doi: 10.1155/2012/895370
– volume: 356
  start-page: 1795
  year: 2000
  ident: key20220302131530_b6-or-47-01-08225
  article-title: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population
  publication-title: Lancet
  doi: 10.1016/S0140-6736(00)03231-1
– volume: 121
  start-page: 1
  year: 2007
  ident: key20220302131530_b2-or-47-01-08225
  article-title: Cancer immunoediting from immune surveillance to immune escape
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2007.02587.x
– volume: 9
  start-page: 895
  year: 2016
  ident: key20220302131530_b42-or-47-01-08225
  article-title: Targeting inflammation in cancer prevention and therapy
  publication-title: Cancer Prev Res (Phila)
  doi: 10.1158/1940-6207.CAPR-16-0209
– volume: 7
  start-page: 14
  year: 2016
  ident: key20220302131530_b46-or-47-01-08225
  article-title: β-glucans: Ex vivo inflammatory and oxidative stress results after pasta intake
  publication-title: Immun Ageing
  doi: 10.1186/s12979-016-0068-x
– volume: 66
  start-page: 131
  year: 2014
  ident: key20220302131530_b67-or-47-01-08225
  article-title: The effect of beta glucan on cisplatin ototoxicity
  publication-title: Indian J Otolaryngol Head Neck Surg
  doi: 10.1007/s12070-013-0623-0
– volume: 38
  start-page: 1327
  year: 2018
  ident: key20220302131530_b39-or-47-01-08225
  article-title: Glucans and cancer: Comparison of commercially available β-glucans-Part IV
  publication-title: Anticancer Res
– volume: 15
  start-page: 1
  year: 2018
  ident: key20220302131530_b3-or-47-01-08225
  article-title: Ageing: From inflammation to cancer
  publication-title: Immun Ageing
  doi: 10.1186/s12979-017-0112-5
– volume: 47
  start-page: 3653
  year: 2020
  ident: key20220302131530_b40-or-47-01-08225
  article-title: The effect of Candida cell wall beta-glucan on treatment-resistant LL/2 cancer cell line: In vitro evaluation
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-020-05459-7
– volume: 8
  start-page: 601
  year: 2020
  ident: key20220302131530_b19-or-47-01-08225
  article-title: Emerging adjuvants for cancer immunotherapy
  publication-title: Front Chem
  doi: 10.3389/fchem.2020.00601
– volume: 25
  start-page: 1
  year: 2021
  ident: key20220302131530_b21-or-47-01-08225
  article-title: Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action
  publication-title: Nat Rev Chem
– volume: 4
  start-page: 62
  year: 2012
  ident: key20220302131530_b41-or-47-01-08225
  article-title: Inflammation and cancer
  publication-title: World J Gastrointest Surg
  doi: 10.4240/wjgs.v4.i3.62
– volume: 51
  start-page: 861
  year: 2007
  ident: key20220302131530_b47-or-47-01-08225
  article-title: Immunological actions of Sophy beta-glucan (beta-1,3-1,6 glucan), currently available commercially as a health food supplement
  publication-title: Microbiol Immunol
  doi: 10.1111/j.1348-0421.2007.tb03982.x
– volume: 2
  start-page: 708
  year: 2014
  ident: key20220302131530_b15-or-47-01-08225
  article-title: Vaccines for cancer prevention: A practical and feasible approach to the cancer epidemic
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-14-0110
– volume: 36
  start-page: 5235
  year: 2018
  ident: key20220302131530_b32-or-47-01-08225
  article-title: β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2018.07.038
– volume: 7
  start-page: 254
  year: 2016
  ident: key20220302131530_b64-or-47-01-08225
  article-title: Failure of elevating calcium induces oxidative stress tolerance and imparts cisplatin resistance in ovarian cancer cells
  publication-title: Aging Dis
  doi: 10.14336/AD.2016.0118
– volume: 183
  start-page: 771
  year: 2020
  ident: key20220302131530_b29-or-47-01-08225
  article-title: Innate immune training of granulopoiesis promotes anti-tumor activity
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.058
– volume: 13
  start-page: 24
  year: 2020
  ident: key20220302131530_b30-or-47-01-08225
  article-title: Functional activities of beta-glucans in the prevention or treatment of cervical cancer
  publication-title: J Ovarian Res
  doi: 10.1186/s13048-020-00626-7
– ident: key20220302131530_b5-or-47-01-08225
  article-title: The genetics of Cancer
  doi: 10.32388/F1TWFR
– volume: 45
  start-page: 199
  year: 2007
  ident: key20220302131530_b49-or-47-01-08225
  article-title: Serum soluble fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus
  publication-title: Folia Histochem Cytobiol
– volume: 27
  start-page: 564
  year: 2011
  ident: key20220302131530_b23-or-47-01-08225
  article-title: Structure of human O-GlcNAc transferase and its complex with a peptide substrate
  publication-title: Nature
  doi: 10.1038/nature09638
– volume: 125
  start-page: 3401
  year: 2015
  ident: key20220302131530_b16-or-47-01-08225
  article-title: Therapeutic cancer vaccines
  publication-title: J Clin Invest
  doi: 10.1172/JCI80009
– ident: key20220302131530_b68-or-47-01-08225
  article-title: OPT-821 with Vaccine Therapy and Beta-Glucan in Treating Younger Patients with High-Risk Neuroblastoma
– volume: 15
  start-page: 9023
  year: 2003
  ident: key20220302131530_b36-or-47-01-08225
  article-title: Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells
  publication-title: Cancer Res
– volume: 2017
  start-page: 8972678
  year: 2017
  ident: key20220302131530_b45-or-47-01-08225
  article-title: Nutraceutical, anti-inflammatory, and immune modulatory effects of β-glucan isolated from yeast
  publication-title: Biomed Res Int
  doi: 10.1155/2017/8972678
– volume: 40
  start-page: 369
  year: 2008
  ident: key20220302131530_b8-or-47-01-08225
  article-title: Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I
  publication-title: Horm Metab Res
  doi: 10.1055/s-2008-1062739
– volume: 106
  start-page: 2067
  year: 2002
  ident: key20220302131530_b9-or-47-01-08225
  article-title: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress
  publication-title: Circulation
  doi: 10.1161/01.CIR.0000034509.14906.AE
– volume: 30
  start-page: 19
  year: 2019
  ident: key20220302131530_b10-or-47-01-08225
  article-title: ‘Hypothalamic Microinflammation’ paradigm in aging and metabolic diseases
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2019.05.021
– volume: 13
  start-page: 242
  year: 2021
  ident: key20220302131530_b63-or-47-01-08225
  article-title: Biological activity of high-purity β-1,3-1,6-glucan derived from the black yeast Aureobasidium pullulans: A literature review
  publication-title: Nutrients
  doi: 10.3390/nu13010242
– volume: 5
  start-page: 127982
  year: 2021
  ident: key20220302131530_b25-or-47-01-08225
  article-title: A systematic review of phytochemicals in oat and buckwheat
  publication-title: Food Chem
  doi: 10.1016/j.foodchem.2020.127982
– volume: 21
  start-page: 405
  year: 2011
  ident: key20220302131530_b56-or-47-01-08225
  article-title: The adjuvant effect of sophy β-glucan to the antibody response in poultry immunized by the avian influenza A H5N1 and H5N2 vaccines
  publication-title: J Microbiol Biotechnol
  doi: 10.4014/jmb.1011.11024
– ident: key20220302131530_b57-or-47-01-08225
  article-title: Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats
  doi: 10.1016/j.clicom.2021.11.001
– volume: 11
  start-page: 1782
  year: 2020
  ident: key20220302131530_b37-or-47-01-08225
  article-title: Could the induction of trained immunity by β-glucan serve as a defense against COVID-19?
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01782
– volume: 3
  start-page: 2808
  year: 2021
  ident: key20220302131530_b38-or-47-01-08225
  article-title: β-Glucans: Wide-spectrum immune-balancing food-supplement-based enteric (β-WIFE) vaccine adjuvant approach to COVID-19
  publication-title: Human Vaccin Immunother
  doi: 10.1080/21645515.2021.1880210
– volume: 18
  start-page: 1787
  year: 2017
  ident: key20220302131530_b13-or-47-01-08225
  article-title: Dysfunctional natural killer cells in the aftermath of cancer surgery
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms18081787
– ident: key20220302131530_b59-or-47-01-08225
  article-title: Beneficial effects of the AFO-202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on non-esterified fatty acid levels in obese diabetic KKAy mice: A comparative study
  publication-title: bioRxiv
– volume: 20
  start-page: 589
  year: 2020
  ident: key20220302131530_b20-or-47-01-08225
  article-title: Strengthening the sting of immunotherapy
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-020-00447-1
– volume: 4
  start-page: 760
  year: 2003
  ident: key20220302131530_b12-or-47-01-08225
  article-title: Excisional surgery for cancer cure: Therapy at a cost
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(03)01282-8
– volume: 4
  start-page: 261
  year: 2016
  ident: key20220302131530_b66-or-47-01-08225
  article-title: Harnessing the immune system to improve cancer therapy
  publication-title: Ann Transl Med
  doi: 10.21037/atm.2016.04.01
– volume: 40
  start-page: 3104
  year: 2021
  ident: key20220302131530_b65-or-47-01-08225
  article-title: Fungal beta-glucans as adjuvants for treating cancer patients-A systematic review of clinical trials
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2020.11.029
– volume: 24
  start-page: 1251
  year: 2019
  ident: key20220302131530_b26-or-47-01-08225
  article-title: Beta glucan: Supplement or drug? from laboratory to clinical trials
  publication-title: Molecules
  doi: 10.3390/molecules24071251
– volume: 2011
  start-page: 908468
  year: 2011
  ident: key20220302131530_b48-or-47-01-08225
  article-title: Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis
  publication-title: Int J Inflam
– volume: 58
  start-page: 105
  year: 2009
  ident: key20220302131530_b11-or-47-01-08225
  article-title: Significant impairment in immune recovery after cancer treatment
  publication-title: Nurs Res
  doi: 10.1097/NNR.0b013e31818fcecd
– year: 2021
  ident: key20220302131530_b58-or-47-01-08225
  article-title: Beneficial effects of novel Aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2021.112243
– volume: 11
  start-page: 1
  year: 2014
  ident: key20220302131530_b44-or-47-01-08225
  article-title: Beneficial effects of black yeast derived 1-3, 1-6 beta glucan-nichi glucan in a dyslipidemic individual of Indian origin-a case report
  publication-title: J Diet Suppl
  doi: 10.3109/19390211.2013.859211
– volume: 15
  start-page: 3820
  year: 2018
  ident: key20220302131530_b53-or-47-01-08225
  article-title: TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2
  publication-title: Oncol Lett
– volume: 3
  start-page: e04177
  year: 2014
  ident: key20220302131530_b54-or-47-01-08225
  article-title: Recognition of tumor cells by dectin-1 orchestrates innate immune cells for anti-tumor responses
  publication-title: Elife
  doi: 10.7554/eLife.04177
– volume: 1625
  start-page: 143
  year: 2017
  ident: key20220302131530_b33-or-47-01-08225
  article-title: Beta-glucan particles as vaccine adjuvant carriers
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-7104-6_11
– volume: 8
  start-page: 564497
  year: 2020
  ident: key20220302131530_b34-or-47-01-08225
  article-title: β-glucan as trained immunity-based adjuvants for rabies vaccines in dogs
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.564497
– volume: 3
  start-page: 370
  year: 2016
  ident: key20220302131530_b7-or-47-01-08225
  article-title: Diabetes-associated dysregulated cytokines and cancer
  publication-title: Integr Cancer Sci Ther
– volume: 2012
  start-page: 195956
  year: 2012
  ident: key20220302131530_b4-or-47-01-08225
  article-title: NK cells in healthy aging and age-associated diseases
  publication-title: J Biomed Biotechnol
  doi: 10.1155/2012/195956
– volume: 94
  start-page: 153
  year: 2018
  ident: key20220302131530_b28-or-47-01-08225
  article-title: Adjuvant immunotherapy for cancer: Both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
  publication-title: Proc Jpn Acad Ser B Phys Biol Sci
  doi: 10.2183/pjab.94.011
– volume: 1403
  start-page: 755
  year: 2016
  ident: key20220302131530_b17-or-47-01-08225
  article-title: Cancer vaccines: A brief overview
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-3387-7_43
– volume: 47
  start-page: 345
  year: 2009
  ident: key20220302131530_b55-or-47-01-08225
  article-title: Aureobasidium-derived soluble branched (1,3–1,6) beta-glucan (Sophy beta-glucan) enhances natural killer activity in Leishmania amazonensis-infected mice
  publication-title: Korean J Parasitol
  doi: 10.3347/kjp.2009.47.4.345
– ident: key20220302131530_b1-or-47-01-08225
– volume: 2
  start-page: 122
  year: 2021
  ident: key20220302131530_b31-or-47-01-08225
  article-title: Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: A review
  publication-title: Explor Target Antitumor Ther
– volume: 39
  start-page: 30
  year: 2019
  ident: key20220302131530_b52-or-47-01-08225
  article-title: The interferon-gamma paradox in cancer
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/jir.2018.0087
– volume: 16
  start-page: 153
  year: 2017
  ident: key20220302131530_b50-or-47-01-08225
  article-title: Tumor-related interleukins: Old validated targets for new anti-cancer drug development
  publication-title: Mol Cancer
  doi: 10.1186/s12943-017-0721-9
– volume: 20
  start-page: 4981
  year: 2019
  ident: key20220302131530_b24-or-47-01-08225
  article-title: Role of phytochemicals in cancer prevention
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20204981
– ident: key20220302131530_b14-or-47-01-08225
  article-title: Immunization: The Basics
– ident: key20220302131530_b60-or-47-01-08225
  article-title: Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM-animal model of non-alcoholic steatohepatitis
  publication-title: bioRxiv
– volume: 26
  start-page: 341
  year: 2018
  ident: key20220302131530_b35-or-47-01-08225
  article-title: Optimizing tumor microenvironment for cancer immunotherapy: β-glucan-based nanoparticles
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2018.00341
– volume: 20
  start-page: 3618
  year: 2019
  ident: key20220302131530_b69-or-47-01-08225
  article-title: Yeast-derived β-glucan in cancer: Novel uses of a traditional therapeutic
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20153618
– ident: key20220302131530_b62-or-47-01-08225
  article-title: Induction of NK activity using Sofy β-glucan. Tosa Biological Society Annual Meeting 2006, Japan
– volume: 18
  start-page: 4032
  year: 2019
  ident: key20220302131530_b27-or-47-01-08225
  article-title: A concise review on the molecular structure and function relationship of β-glucan
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20164032
– volume: 7
  start-page: 2391
  year: 2019
  ident: key20220302131530_b51-or-47-01-08225
  article-title: IL-6 activities in the tumour microenvironment. Part 1
  publication-title: Open Access Maced J Med Sci
  doi: 10.3889/oamjms.2019.589
– volume: 26
  start-page: 4131
  year: 2006
  ident: key20220302131530_b61-or-47-01-08225
  article-title: Antitumor and antimetastatic activity of a novel water-soluble low molecular weight beta-1, 3-D-glucan (branch beta-1,6) isolated from Aureobasidium pullulans 1A1 strain black yeast
  publication-title: Anticancer Res
SSID ssj0027069
Score 2.4070277
SecondaryResourceType review_article
Snippet The incidence of cancer, which is the second leading cause of mortality globally, continues to increase, although continued efforts are being made to identify...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
SubjectTerms Adjuvants, Vaccine - administration & dosage
Aging
Animals
Antigens
beta-Glucans - immunology
Cancer therapies
Chemotherapy
Cytotoxicity
Diabetes
Disease prevention
DNA damage
Health risk assessment
Humans
Hyperglycemia
Hypothalamus
Immune system
Immunocompromised Host - immunology
Inflammation
Metabolic disorders
Mortality
Neoplasms - immunology
Neoplasms - prevention & control
Older people
Phytochemicals
Prostate cancer
Radiation therapy
Surgery
Vaccines
Title β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)
URI https://www.ncbi.nlm.nih.gov/pubmed/34779494
https://www.proquest.com/docview/2605513105
https://www.proquest.com/docview/2597818307
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3bShxBEC0ShZAXiTGXjUY6ECEhdJzu6ds-BRVFAopIDPs29G2JIjPrXvIP_k4-xG-ya6Z3TB7M63QxA316qk5XV9cB-Mi108IGRS1TkQofAzXKjKnTRXQqKBPajeLJqTq-EN9HcpQTbrNcVrn0ia2jDo3HHPku8m7JEhmR3yY3FFWj8HQ1S2g8hVVsXYYlXXr014araCXtUL2alqUcdYXvKUTz3QZ7gXL2NcVH-W9IeoRntvHm6AWsZaJI9jpk1-FJrF_Cs5N8FL4Bt3d_2npzW5Pf1uMzYsPVIhHjOVk2CieJkRKPuE5JX1FOsjQPucSrIZHE-hdatEOf9unPvQPMO30mlzXBa5hYStSZNlh-Pm3SwoiBTHrhr9kruDg6_HFwTLOuAvWl1HNacs2iiswmemJj8NwNnRWssKWJnjObGKBxzg2HYx1lqa2wkUkdCu5FEcZOlK9hpW7q-BaIYNifnkeVmJvQgRmfUJCB2eQpjHFqAF-WU1v53HQctS-uq7T5QCCqZlohEBUCMYCd3nrSNdt4xG5riVKVf7lZ9bBABvChH05zgicgto7NItlIbPFlkl8bwJsO3f5DpdDJNw3Fu_-_fBOec7wB0WZhtmBlPl3E94mXzN12u_i2YXX_8PTs_B4g3-Q3
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9RADLbKVgIuiDcLBQaJSiA0NDOZZJIDQm1ptaXdFUIt2luY14oilCz7APET-DMc-CH8Juw8tuJQbr0m1kQaO_bnGdsfwFOprVbGp9yINHDlgudZmk241VGwqU8zXyeKw1E6OFFvx8l4DX51vTBUVtn5xNpR-8rRGfkW4e5EIBhJXk-_cmKNotvVjkKjMYvD8OM7pmzzVwdvUL-bUu7vHe8OeMsqwF2c6AWPpRYhDcJgcDbBO2lza5SITJwFJ4VB_JNZa_N8okMSa6NMEIn2kXQq8hOrYlz3EqyrGFOZHqzv7I3evT9L8aKaRI_4snkcJ-Om1B5BgdyqaPqoFC8xIif_BsFzkG0d4favw7UWmrLtxpZuwFoob8LlYXv5fgt-_vldV7ibkn0zjp4x4z8vEYovWDeanCEGZo4sacZWNeysJQNip9SMElgoP5FE_erZDv-wvUsnXc_Zacmo8ZOKlxrRigreZxWaYvBsuqIam9-GkwvZ8zvQK6sy3AOmBE3ElyFFrKi0F5nLMePxwqBvyjKb9uFFt7WFa8ecE9vGlwLTHVJEUc0KUkRBiujD5kp62oz3OEduo9NS0f7k8-LMJPvwZPUa94TuXEwZqiXKJDRULENP2oe7jXZXH4qVRm-Yq_v_X_wxXBkcD4-Ko4PR4QO4Kqn_oj4D2oDeYrYMDxEVLeyj1hQZfLxo6_8L1vwhkw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcUHlvW8BIVAIhs7HjxMkBodKyaimtOFC0t9SvFUUo2e4DxE_g73DkR_CbmMkLOJRbr8nIiTyfx9_Y8wB4LLXVyviUG5EGrlzwPEuzCbc6Cjb1aeZrR_HoON0_UW_GyXgFfna5MBRW2dnE2lD7ytEZ-ZB4dyKQjCTDSRsW8W5v9HJ6zqmDFN20du00Gogchm9f0X2bvzjYQ11vSzl6_X53n7cdBriLE73gsdQipEEY3KhN8E7a3BolIhNnwUlhkAtl1to8n-iQxNooE0SifSSdivzEqhjHvQJXdYx_hmtJj_9y9qK6nR51zuZxnIyboHukB3JYUR1SKZ7j3pz8ux1ewHHrvW60Dtdbksp2GlTdgJVQ3oS1o_Ya_hZ8__WjjnU3JftiHD1jxn9aIilfsK5IOUM2zBxhasb6aHbWtgViZ5SWElgoP5JE_erJK_5hZ5fOvJ6ys5JRCiiFMTWiFYW-zyoEZfBs2jcdm9-Gk0uZ8TuwWlZluAdMCaqNL0OKrFFpLzKXo-_jhUErlWU2HcCzbmoL1xY8p74bnwt0fEgRRTUrSBEFKWIA2730tCn0cYHcVqelol3u8-IPOAfwqH-Nc0K3L6YM1RJlEiovlqFNHcDdRrv9h2Kl0S7mauP_gz-ENcR88fbg-HATrklKxKgPg7ZgdTFbhvtIjxb2QY1DBqeXDfzfGkkkYw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%CE%B2%E2%80%91glucan+vaccine+adjuvant+approach+for+cancer+treatment+through+immune+enhancement+%28B%E2%80%91VACCIEN%29+in+specific+immunocompromised+populations+%28Review%29&rft.jtitle=Oncology+reports&rft.au=Ikewaki%2C+Nobunao&rft.au=Dedeepiya%2C+Vidyasagar+Devaprasad&rft.au=Raghavan%2C+Kadalraja&rft.au=Rao%2C+Kosagi-Sharaf&rft.date=2022-01-01&rft.issn=1791-2431&rft.eissn=1791-2431&rft.volume=47&rft.issue=1&rft_id=info:doi/10.3892%2For.2021.8225&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1021-335X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1021-335X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1021-335X&client=summon